Legal & General Group Plc acquired a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,119,264 shares of the medical equipment provider’s stock, valued at approximately $431,890,000. Legal & General Group Plc owned approximately 0.70% of Boston Scientific as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the company. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific in the second quarter valued at $25,000. FWL Investment Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific in the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific in the 1st quarter worth $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Insider Activity
In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.
Analyst Upgrades and Downgrades
Boston Scientific Stock Performance
BSX stock opened at $49.86 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm has a market cap of $72.26 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.07 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The stock’s 50 day simple moving average is $46.44 and its 200 day simple moving average is $57.14.
Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.
Boston Scientific declared that its board has initiated a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Stories
- Five stocks we like better than Boston Scientific
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
